Undertreatment of erectile dysfunction: Claims analysis of 6.2 million patients

Journal of Sexual Medicine

Volumn 11, Issue 10, 2014, Pages 2546-2553

  Frederick, Luke R ^a   Cakir, Omer Onur ^b   Arora, Hans ^b   Helfand, Brian T ^c   McVary, Kevin T ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Comorbidity; Erectile Dysfunction; Hypogonadism; Medical Intervention of Erectile Dysfunction; Phosphodiesterase 5 Inhibitors; Treatment

Indexed keywords

PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; VARDENAFIL;

ADULT; ANDROGEN THERAPY; ARTICLE; COMORBIDITY; DEMOGRAPHY; ERECTILE DYSFUNCTION; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MONOTHERAPY; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SLEEP DISORDER; AGED; INSURANCE; PREVALENCE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

ADULT; AGED; COMORBIDITY; ERECTILE DYSFUNCTION; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PREVALENCE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 84908547342     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12647     Document Type: Article

References (21)

1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993;270:83-90.
2. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: Results from the health professionals follow-up study. Ann Intern Med 2003;139:161-168.
3. Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84:50-56.
4. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
5. McVary KT. Sexual dysfunction. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison's principles of internal medicine. 17th edition, Section 8, Chapter 49. Chicago, IL: McGraw-Hill Publishers; 2008:271-275.
6. Kohler TS, McVary KT. The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. Eur Urol 2009;55:38-48.
7. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O'Leary MP, Puppo P, Robertson C, Giuliano F. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol 2003;44:637-649.
8. McVary KT. Clinical practice. Erectile dysfunction. N Eng J Med 2007;357:2472-2481.
9. Morelli A, Corona G, Filippi S. Which patients with sexual dysfunction are suitable for testosterone replacement therapy? J Endocrinol Invest 2007;30:880-888.
10. Shabsigh R. Testosterone therapy in erectile dysfunction and hypogonadism. J Sex Med 2005;2:785-792.
11. Chew KK, Earle CM, Stuckey BG, Jamrozik K, Keogh EJ. Erectile dysfunction in general medicine practice: Prevalence and clinical correlates. Int J Impot Res 2000;12:41-45.
12. Ansong KS, Lewis C, Jenkins P, Bell J. Help-seeking decisions among men with impotence. Urology 1998;52:834-837.
13. Baldwin K, Ginsberg P, Harkaway RC. Under-reporting of erectile dysfunction among men with unrelated urologic conditions. Int J Impot Res 2003;15:87-89.
14. Montague DK. Penile prosthesis implantation in the era of medical treatment for erectile dysfunction. Urol Clin North Am 2011;38:217-225.
15. Cappelleri JC, Rosen RC. The Sexual Health Inventory for Men (SHIM): A 5-year review of research and clinical experience. Int J Impot Res 2005;17:307-319.
16. Fink HA, Mac Donald R, Rutks IR, Nelson DB, Wilt TJ. Sildenafil for male erectile dysfunction: A systematic review and meta-analysis. Arch Intern Med 2002;162:1349-1360.
17. Urciuoli R, Cantisani TA, Carlini IM, Giuglietti M, Botti FM. Prostaglandin E1 for treatment of erectile dysfunction. Cochrane Database Syst Rev 2004;(2):CD001784.
18. Jaffe JS, Antell MR, Greenstein M, Ginsberg PC, Mydlo JH, Harkaway RC. Use of intraurethral alprostadil in patients not responding to sildenafil citrate. Urology 2004;63:951-954.
19. Jain P, Rademaker AW, McVary KT. Testosterone supplementation for erectile dysfunction: Results of a meta-analysis. J Urol 2000;164:371-375.
20. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006;91:1995-2010.
21. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, etal. Adverse events associated with testosterone administration. N Engl J Med 2010;363:109-122. doi: 10.1056/NEJMoa1000485. Epub 2010 Jun 30.